- A new payload class: RVU602 is a proprietary, potentially first-in-class ADC payload with a mechanism of action orthogonal to both topoisomerase I (TOPO1) inhibitors and microtubule inhibitors – the two payload classes behind nearly all approved and late-stage ADCs.
- Designed to overcome key limitations of current ADCs: RVU602 is essentially unaffected by P-gp-mediated drug efflux, retains activity in TOPO1 inhibitor-resistant models, and has the potential to induce immunogenic cell death.
- Strong in-vivo proof of concept: a sacituzumab-based (anti-TROP2) RVU602 ADC achieved complete responses in 100% of animals at 10 mg/kg once weekly in the HCC70 triple-negative breast cancer (TNBC) xenograft model.
- Broad applicability: RVU602 was successfully conjugated to four clinically validated antibodies (anti-TROP2, anti-EGFR, anti-c-MET and anti-HER2), yielding stable ADCs with sub-nanomolar potency and complete tumour cell killing in-vitro.
Ryvu Therapeutics, a clinical-stage drug discovery and development company focused on novel therapies that address emerging targets in oncology, presents preclinical in-vivo data on ADCs based on RVU602, its proprietary novel ADC payload, at the World ADC Congress, October 12-15, 2026, in San Diego, CA.
Nearly all approved and late-stage antibody-drug conjugates (ADCs) rely on just two payload classes: microtubule inhibitors (e.g., MMAE) and topoisomerase I inhibitors (e.g., DXd, SN-38). Shared mechanisms mean shared failure modes: tumours progressing on one TOPO1 inhibitor-based ADC often cross-resist to the next, drug efflux transporters such as P-gp blunt activity, and overlapping toxicities limit sequencing and combinations. As the antibody targets of the leading ADCs become increasingly crowded, the next gains in ADC performance are expected to come from novel payloads.
RVU602 was discovered on Ryvu’s payload discovery platform, which combines patient-derived models, high-throughput phenotypic screening and transcriptomic mechanism-of-action profiling with in-house medicinal chemistry optimized for potency, efflux resistance and conjugation-ready stability. The data presented at the World ADC Congress show that RVU602 addresses four unmet needs in a single payload: activity in TOPO1 inhibitor-resistant disease, no efflux liability, an orthogonal mechanism of action and built-in immunomodulatory potential.
Krzysztof Brzózka, Ph.D., Chief Scientific Officer of Ryvu Therapeutics, said: “RVU602 is the first payload from our ADC discovery platform and a strong validation of our phenotypic, patient-derived approach to payload discovery. Rather than optimising yet another topoisomerase or tubulin inhibitor, we set out to find a genuinely new mechanism. RVU602 not only kills tumour cells that are resistant to today’s leading ADC payloads, but also triggers immunogenic cell death, which opens the door to rational combinations with immunotherapy. Complete responses in all animals treated with our TROP2-directed ADC are a very encouraging in-vivo proof of concept.”
Paweł Przewięźlikowski, Chief Executive Officer of Ryvu Therapeutics, said: “Less than two years after launching our first in-house ADC programme, supported by non-dilutive funding, we are presenting in-vivo proof-of-concept data for a proprietary first-in-class payload that we believe can differentiate next-generation ADCs. Novel payloads are attracting significant interest in ADC partnering. RVU602 adds a new, platform-type opportunity to Ryvu’s portfolio, which we intend to advance towards partnering, while we continue to progress our clinical programs.”
Details on the poster presentation are as follows:
Poster Title: RVU602: A Non-TOPO1/Non-Tubulin Payload for Next-Generation ADCs
Poster Number: 96
Session date and time: Wednesday, October 14, 2026, 10:00 AM PDT (7:00 PM CEST)
What differentiates the RVU602 payload
- A third mechanistic class. Transcriptomic profiling shows that RVU602 induces neither the replication-stress signature characteristic of TOPO1 inhibitors nor the mitotic-arrest signature of tubulin inhibitors. This opens the option of sequencing RVU602-based ADCs after, or combining them with, DXd- and MMAE-based ADCs.
- Active in TOPO1 inhibitor-resistant tumours. In cells carrying a TOPO1 mutation, deruxtecan (DXd) lost more than 100-fold potency, whereas RVU602 retained full activity (resistant/parental EC50 ratio of 1.0-4.4). This is directly relevant for the growing population of patients progressing on TOPO1 inhibitor-based ADCs.
- No efflux liability. In a P-gp-high cell line, RVU602 potency was essentially unaffected by P-gp inhibition (1.6-fold shift, versus 3.7-fold for DXd and 12-fold for MMAE), indicating that RVU602 overcomes a major efflux-driven resistance route.
- Built-in immunomodulatory activity. Beyond direct cytotoxicity, RVU602 induces the release of extracellular ATP, a hallmark of immunogenic cell death, supporting the potential of RVU602-based ADCs in combination with immune checkpoint blockade.
- Deep, pan-tumour cytotoxicity. Across a panel of 272 cancer cell lines, RVU602 showed broad cytotoxic activity and a markedly deeper response than DXd.
ADC validation and in-vivo proof of concept
- RVU602 was conjugated to four antibodies – sacituzumab (anti-TROP2), cetuximab (anti-EGFR), telisotuzumab (anti-c-MET) and trastuzumab (anti-HER2). The resulting ADCs showed high monomeric content (>95%), high drug-to-antibody ratios (DAR 6-8) and low payload release in plasma (<1% in mouse and <15% in human plasma after 7 days).
- RVU602 ADCs combined sub-nanomolar potency with complete tumor cell killing in-vitro, outperforming datopotamab deruxtecan (Dato-DXd) and matching a cetuximab-MMAE comparator.
- In patient-derived TROP2-positive TNBC cells, the RVU602 ADC achieved low-nanomolar potency (EC50 0.4-7.5 nM) with 100% efficacy and 30- to 250-fold selectivity over the isotype control, supporting its translational potential.
- In the TROP2-positive HCC70 TNBC xenograft model, the sacituzumab-RVU602 ADC led to complete responses in 100% of animals after two doses at 10 mg/kg once weekly (QW) and in 83% of animals after four doses at 5 mg/kg twice weekly (BIW). Strong target engagement in tumours correlated with tumour growth inhibition. Sacituzumab govitecan (20 mg/kg QW) was included as a reference arm.
Together, these data validate RVU602 across multiple antibody targets and models, including settings resistant to topoisomerase I inhibitors, and support RVU602 as a differentiated payload for next-generation ADCs.



















